Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Autologous Mesenchymal Stem Cells for Ischemic Stroke (Phase 3)
KCT0000574Phase 3Not yet recruiting
- Sponsor
- Pharmicell Co., Ltd.
- Start
- Nov 2012
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of autologous mesenchymal stem cells in ischemic stroke, sponsored by Pharmicell Co., Ltd.. Planned start Nov 2012; status: not yet recruiting.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on KCT0000574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000574.